Most of the sesterterpenes characterized exhibited anti‐liver fibrosis activity in vitro by inhibiting the production of collagen COL1A1, potentially via the TGF‐β/Smad signaling pathway, since the expression of TGF‐β1 and p‐Smad2/3 were both inhibited by compound 9. The gene discussed is SMAD2; the disease is Hepatic fibrosis.